235 related articles for article (PubMed ID: 30054466)
1. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications.
Lee D; Jang MK; Seo JH; Ryu SH; Kim JA; Chung YH
Exp Mol Med; 2018 Jul; 50(7):1-12. PubMed ID: 30054466
[TBL] [Abstract][Full Text] [Related]
2. Diverse roles of arrest defective 1 in cancer development.
Chaudhary P; Ha E; Vo TTL; Seo JH
Arch Pharm Res; 2019 Dec; 42(12):1040-1051. PubMed ID: 31813105
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Lysine Acetyltransferase Activity of Recombinant Human ARD1/NAA10.
Vo TTL; Park JH; Lee EJ; Nguyen YTK; Han BW; Nguyen HTT; Mun KC; Ha E; Kwon TK; Kim KW; Jeong CH; Seo JH
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013195
[TBL] [Abstract][Full Text] [Related]
4. Versatility of ARD1/NAA10-mediated protein lysine acetylation.
Vo TTL; Jeong CH; Lee S; Kim KW; Ha E; Seo JH
Exp Mol Med; 2018 Jul; 50(7):1-13. PubMed ID: 30054464
[TBL] [Abstract][Full Text] [Related]
5. ARD1/NAA10 acetylation in prostate cancer.
Kuhns KJ; Zhang G; Wang Z; Liu W
Exp Mol Med; 2018 Jul; 50(7):1-8. PubMed ID: 30054487
[TBL] [Abstract][Full Text] [Related]
6. Autoacetylation regulates differentially the roles of ARD1 variants in tumorigenesis.
Seo JH; Park JH; Lee EJ; Vo TT; Choi H; Jang JK; Wee HJ; Ahn BJ; Cha JH; Shin MW; Kim KW
Int J Oncol; 2015 Jan; 46(1):99-106. PubMed ID: 25338643
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of arrest-defective protein 1 expression in hepatocellular carcinoma: a novel predictor of microvascular invasion.
Shim JH; Chung YH; Kim JA; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Yu E; Lee YJ
Dig Dis; 2012; 30(6):603-8. PubMed ID: 23258102
[TBL] [Abstract][Full Text] [Related]
8. N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10.
Lee MN; Kweon HY; Oh GT
Exp Mol Med; 2018 Jul; 50(7):1-11. PubMed ID: 30054454
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal Acetyltransferase Naa10/ARD1 Does Not Acetylate Lysine Residues.
Magin RS; March ZM; Marmorstein R
J Biol Chem; 2016 Mar; 291(10):5270-7. PubMed ID: 26755727
[TBL] [Abstract][Full Text] [Related]
10. Nuclear translocation of hARD1 contributes to proper cell cycle progression.
Park JH; Seo JH; Wee HJ; Vo TT; Lee EJ; Choi H; Cha JH; Ahn BJ; Shin MW; Bae SJ; Kim KW
PLoS One; 2014; 9(8):e105185. PubMed ID: 25133627
[TBL] [Abstract][Full Text] [Related]
11. Arrest defective 1 regulates the oxidative stress response in human cells and mice by acetylating methionine sulfoxide reductase A.
Shin SH; Yoon H; Chun YS; Shin HW; Lee MN; Oh GT; Park JW
Cell Death Dis; 2014 Oct; 5(10):e1490. PubMed ID: 25341044
[TBL] [Abstract][Full Text] [Related]
12. The N-end rule pathway enzyme Naa10 supports epiblast specification in mouse embryonic stem cells by modulating FGF/MAPK.
Takekoshi D; Tokuzawa Y; Sakanaka M; Kato H
In Vitro Cell Dev Biol Anim; 2019 May; 55(5):355-367. PubMed ID: 30993557
[TBL] [Abstract][Full Text] [Related]
13. ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis.
Zhang Y; Zhou H; Tao Y; Liu X; Yuan Z; Nie C
Cell Death Dis; 2018 Aug; 9(9):860. PubMed ID: 30154412
[TBL] [Abstract][Full Text] [Related]
14. NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
Le MK; Vuong HG; Nguyen TTT; Kondo T
J Neuropathol Exp Neurol; 2023 Jun; 82(7):650-658. PubMed ID: 37253389
[TBL] [Abstract][Full Text] [Related]
15. NAA10 as a New Prognostic Marker for Cancer Progression.
Kim SM; Ha E; Kim J; Cho C; Shin SJ; Seo JH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126484
[TBL] [Abstract][Full Text] [Related]
16. NAA10-related syndrome.
Wu Y; Lyon GJ
Exp Mol Med; 2018 Jul; 50(7):1-10. PubMed ID: 30054457
[TBL] [Abstract][Full Text] [Related]
17. Hydroxylation of the Acetyltransferase NAA10 Trp38 Is Not an Enzyme-Switch in Human Cells.
Ree R; Krogstad K; McTiernan N; Jakobsson ME; Arnesen T
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769235
[TBL] [Abstract][Full Text] [Related]
18. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10.
Yang H; Li Q; Niu J; Li B; Jiang D; Wan Z; Yang Q; Jiang F; Wei P; Bai S
Oncotarget; 2016 Jan; 7(3):2709-20. PubMed ID: 26646451
[TBL] [Abstract][Full Text] [Related]
19. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.
Li Q; Liu X; Jin K; Lu M; Zhang C; Du X; Xing B
BMC Cancer; 2017 Aug; 17(1):605. PubMed ID: 28859621
[TBL] [Abstract][Full Text] [Related]
20. NAA10 promotes proliferation of renal cell carcinoma by upregulating UPK1B.
Zhang ZY; Zhang JL; Zhao LX; Yang Y; Guo R; Zhou N; Liu YR; Zheng GP
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11553-11560. PubMed ID: 33275221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
